Barclays Reaffirms Equal Weight Rating for uniQure (QURE)

uniQure N.V. (NASDAQ:QURE) is one of the 7 best small-cap healthcare stocks to buy according to hedge funds.

On March 23, Barclays analyst Eliana Merle reduced the price target on uniQure N.V. (NASDAQ:QURE) from $31 to $25. The analyst reaffirmed an Equal Weight rating on the shares, which still offer a potential upside of more than 69% despite the downward revision.

Romaset/Shutterstock.com

Although the exit of Vinay Prasad from the FDA could have a positive impact, there are still risks associated with the company’s regulation. According to the analyst, a Phase 3 clinical trial for Huntington’s disease will be required for the company.

On March 11, Mizuho increased the firm’s price target on uniQure N.V. (NASDAQ:QURE) from $12 to $35. The firm upgraded the rating from Neutral to Outperform, which currently offers an upside potential of 137%.

Mizuho cited the recent departure of Dr. Vinay Prasad from the U.S. Food and Drug Administration, noting it could signal a more flexible regulatory environment. It added that this shift may reopen a path toward approval based on existing data or alternative trial designs, supporting a more constructive outlook on the shares.

uniQure N.V. (NASDAQ:QURE) is focused on developing therapeutics for patients suffering from rare and deadly diseases. Its product portfolio includes HEMGENIX, AMT-260, AMT-162, and AMT- 130. It targets various medical conditions such as hemophilia B, Huntington’s disease, mesial temporal lobe epilepsy, and more.

While we acknowledge the risk and potential of QURE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than QURE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.